ARGX - Argenx

-

$undefined

N/A

(N/A)

Argenx NASDAQ:ARGX Argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer.

Location: Willemstraat 5, Noord Brabant, 4811 AH, Netherlands | Website: https://www.argenx.com/ | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

32.26B

Cash

3.379B

Avg Qtr Burn

-20.69M

Short % of Float

3.66%

Insider Ownership

0.00%

Institutional Own.

56.73%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
VYVGART Hytrulo (SC Efgartigimod) Details
Autoimmune disease, Myasthenia gravis

Approved

Quarterly sales

VYVGART Hytrulo (Efgartigimod) Details
Chronic inflammatory disorder

Approved

Quarterly sales

VYVGART SC pre-filled syringe (PFS) Details
Myasthenia gravis, Autoimmune disease, Chronic inflammatory disorder

PDUFA

Approval decision

Empasiprubart Details
Neuropathy, Neuromuscular disease, Multifocal motorneuropathy

Phase 3

Data readout

Efgartigimod Details
Primary immune thrombocytopenia

Phase 3

Update

Phase 3

Initiation

Efgartigimod Details
Sjögren-Larsson Syndrome

Phase 3

Initiation

Efgartigimod Details
Dermatomyositis , Anti-synthetase syndrome, Immune-mediated necrotizing myopathy, Idiopathic inflammatory myopathy / myositis

Phase 2/3

Data readout

Empasiprubart Details
Dermatomyositis

Phase 2

Data readout

Empasiprubart Details
Delayed graft function

Phase 2

Data readout

Efgartigimod Details
Post-COVID Postural Orthostatic Tachycardia Syndrome

Phase 2

Data readout

ARGX -119 Details
Amyotrophic lateral sclerosis

Phase 2a

Data readout

ARGX -119 Details
Congenital myasthenic syndrome

Phase 1b

Data readout

ARGX-213 Details
no known indication

Phase 1

Data readout

ARGX-121 Details
no known indication

Phase 1

Data readout

ARGX-109 Details
Inflammatory disease

Phase 1

Data readout

Efgartigimod Details
Mucosal Pemphigus Vulgaris

Failed

Discontinued